ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

9:00AM-11:00AM: Abstract Number: 1581

Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review

Immunological Complications of Therapy Poster

9:00AM-11:00AM: Abstract Number: 1617

New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1854

NGF/TrkA System Regulates Pain and the Pannus Formation: Targeting NGF-TrkA in Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1631

No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program

Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies

9:00AM-11:00AM: Abstract Number: 1896

No Relationship Between Lumbar Bone Mineral Density and Syndesmophyte Formation at the Same Level – A Multilevel Analysis in Patients with Radiographic Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

9:00AM-11:00AM: Abstract Number: 1912

Novel Role of Thy-1 (CD90) in the Pathogenesis of Skin Fibrosis

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1642

Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1765

Obstetric Outcomes in Younger Women Less Than 21 Years of Age Compared to Women Between Age 21 and 25 Years with Rheumatic Disease

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1921

Ongoing Vascular 18F-FDG Uptake Despite Clinical Remission in Patients Receiving Tocilizumab for Large Vessel Vasculitis-Giant Cell Arteritis: Single Universitary Center Experience of 30 Patients

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1566

Onset and Disease Course of Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitor Therapy at a Single Institution

Immunological Complications of Therapy Poster

9:00AM-11:00AM: Abstract Number: 1553

Optical Tomography Can Accurately Diagnose Lupus Arthritis

Imaging of Rheumatic Diseases Poster

9:00AM-11:00AM: Abstract Number: 1941

Outcome of Giant Cell Arteritis Patients Who Were Primarily Admitted for Venous Thromboembolism Events

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1841

Outcomes After Hydroxychloroquine Reduction or Discontinuation in a Multinational Inception Cohort of Systemic Lupus

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: L01

Outcomes of COVID-19 Infection in Patients with Rheumatic Diseases in a Multicenter Healthcare System: A Comparative Cohort Study

Late-Breaking Posters

9:00AM-11:00AM: Abstract Number: 1574

Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review

Immunological Complications of Therapy Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].